Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient. [PDF]
Oka S, Akagi Y, Mituyoshi T, Ono K.
europepmc +1 more source
Extracellular vesicles enhance the in vivo antitumor effects of millettia species-derived compounds in chronic myelogenous leukemia therapy. [PDF]
Xie Z +5 more
europepmc +1 more source
Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2 BCR::ABL1 fusion transcripts: a case report and review of the literature. [PDF]
Xu Y +9 more
europepmc +1 more source
Enabling biomedical technologies for chronic myelogenous leukemia (CML) biomarkers detection. [PDF]
Pinnenti M, Sami MA, Hassan U.
europepmc +1 more source
Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib. [PDF]
Klaihmon P +4 more
europepmc +1 more source
Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study. [PDF]
Huang CE +6 more
europepmc +1 more source
Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia
Mathilde Chanut +28 more
doaj +1 more source

